Saturday 17 October 2026
Export DCOY’s income statement to Excel — free account
Decoy Therapeutics Inc
DCOY Healthcare Biotechnology
In the quarter to June 2026, revenue fell 84.6%, EPS grew 94.5% and free cash flow fell 212.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.17
0.06
−4.88%
Follow DCOY
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | 0.04 |
P/S ratio |
— | — | — | 1.85 | |
P/FCF ratio |
— | — | — | 0.00 | |
P/Operating CF |
— | — | — | (1.44) | |
P/B ratio |
— | — | — | 0.89 | |
Price to Tangible BV |
— | — | — | 0.00 | |
EV/Sales |
— | — | — | (1.93) | |
EV/EBITDA |
— | — | — | 0.27 | |
EV/Operating CF |
— | — | — | 0.48 | |
EV/FCF |
— | — | — | 0.38 | |
Quick Ratio |
2.60 | 2.07 | 1.72 | 1.77 | |
Current Ratio |
3.28 | 2.13 | 1.84 | 1.83 | |
Net Debt/EBITDA |
5.38 | 1.19 | 3.43 | 3.47 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.40 | |
Operating CF/Net income |
1.89 | 0.13 | 1.30 | 1.12 | |
Capex/Depreciation |
0.00 | (147.95) | 0.00 | (3.09) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 573.07% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 582.91% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
— | — | — | 0.00% | |
Graham Net Nets |
— | — | — | 1.02 | |
Graham Number |
— | — | — | 183.17 | |
Earnings Yield |
— | — | — | 2,553.35% | |
Free Cash Flow Yield |
— | — | — | (272.98%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.43 | |
Operating CF per Share |
(41.06) | (11.72) | (5.43) | (4.98) | |
Capex per Share |
0.00 | (5.95) | 0.00 | (0.08) | |
Free Cash Flow per Share |
(41.06) | (17.66) | (5.43) | (5.06) | |
Cash per Share |
119.94 | 110.41 | 14.70 | 15.58 | |
Shareholders Equity per Share |
105.94 | 60.71 | 7.29 | 8.12 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
105.94 | 60.71 | 7.29 | 8.12 | |
Free Cash Flow |
(1.65) | (1.71) | (2.89) | (2.69) | |
Working Capital |
4.22 | 5.82 | 3.81 | 3.89 | |
Capital Expenditures |
— | (0.58) | — | (0.04) | |
Net Current Asset Value |
4.22 | 5.82 | 3.81 | 3.89 | |
EV/EBIT |
— | — | — | 0.27 | |
Capex to Sales |
— | 0.00 | — | 0.19 | |
Price to Operating Income |
— | — | — | 0.00 | |
| Other line items | |||||
Average Payables |
0.64 | 0.94 | 1.20 | 1.40 | |
Average Assets |
4.98 | 7.04 | 5.38 | 5.20 | |
Average Common Equity |
3.59 | 3.70 | 1.97 | 1.75 |
Columns are period end dates